Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
Help & Tutorial 
Cancel anytime
- Chart
- Upturn Summary
- Highlights
- Revenue
- Valuation
Upturn AI SWOT - About
Telix Pharmaceuticals Limited (TLX)
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)
Stock price based on last close (see disclosures)
- ALL
- YEAR
- MONTH
- WEEK
Upturn Advisory Summary
10/15/2025: TLX (1-star) is currently NOT-A-BUY. Pass it for now.
Upturn Star Rating
Not Recommended Performance
These Stocks/ETFs, based on Upturn Advisory, consistently fall short of market performance, signaling caution before investing.
Number of Analysts
2 Analysts rated it
Very few follow this stock; limited insights, higher-risk early investing.
1 Year Target Price $20.19
1 Year Target Price $20.19
| 2 | Strong Buy |
| 0 | Buy |
| 0 | Hold |
| 0 | Sell |
| 0 | Strong Sell |
Analysis of Past Performance
Type Stock | Historic Profit -18.41% | Avg. Invested days 18 | Today’s Advisory PASS |
Upturn Star Rating | Upturn Advisory Performance  1.0 | Stock Returns Performance  1.0 |
| Profits based on simulation | Last Close 10/15/2025 |
Key Highlights
Company Size Mid-Cap Stock | Market Capitalization 5.23B USD | Price to earnings Ratio 173.44 | 1Y Target Price 20.19 |
Price to earnings Ratio 173.44 | 1Y Target Price 20.19 | ||
Volume (30-day avg) 2 | Beta 2.38 | 52 Weeks Range 8.93 - 30.36 | Updated Date 08/23/2025 |
52 Weeks Range 8.93 - 30.36 | Updated Date 08/23/2025 | ||
Dividends yield (FY) - | Basic EPS (TTM) 0.09 |
Analyzing Revenue: Products, Geography and Growth
Revenue by Products
Product revenue - Year on Year
Revenue by Geography
Earnings Date
Report Date 2025-10-23 | When - | Estimate - | Actual - |
Profitability
Profit Margin 7.62% | Operating Margin (TTM) 9.49% |
Management Effectiveness
Return on Assets (TTM) 7.97% | Return on Equity (TTM) 20.49% |
Valuation
Trailing PE 173.44 | Forward PE 77.52 | Enterprise Value 5203158084 | Price to Sales(TTM) 8.09 |
Enterprise Value 5203158084 | Price to Sales(TTM) 8.09 | ||
Enterprise Value to Revenue 12.96 | Enterprise Value to EBITDA 113.13 | Shares Outstanding 334724000 | Shares Floating 282348658 |
Shares Outstanding 334724000 | Shares Floating 282348658 | ||
Percent Insiders - | Percent Institutions - |
Upturn AI SWOT
Telix Pharmaceuticals Limited
Company Overview
History and Background
Telix Pharmaceuticals Limited is a biopharmaceutical company focused on developing diagnostic and therapeutic products based on molecularly targeted radiation (MTR) technology. Founded in 2015, it has achieved significant milestones in advancing its pipeline of oncology products, particularly in prostate cancer imaging and therapy.
Core Business Areas
- Diagnostic Imaging: Develops and commercializes imaging agents for the detection and staging of various cancers, with a focus on prostate cancer, renal cancer, and glioblastoma.
- Therapeutics: Develops radiopharmaceutical therapies targeting cancer cells, utilizing the same targeting molecules as its imaging agents to deliver therapeutic isotopes.
Leadership and Structure
The leadership team consists of experienced executives in the pharmaceutical and biotechnology industries. The organizational structure includes departments for research and development, clinical trials, commercialization, and regulatory affairs.
Top Products and Market Share
Key Offerings
- Illuccix: A PSMA-targeting PET imaging agent for prostate cancer. Illuccix has a strong market position due to its high sensitivity and specificity in detecting prostate cancer. Key competitors include Lantheus Holdings (LNTH) and GE HealthCare Technologies Inc. (GEHC). Telix Pharmaceuticals has a significant revenue contribution from this product.
- TLX591: A radiopharmaceutical therapy targeting PSMA-expressing prostate cancer cells. Still in clinical development, if approved, will compete with Pluvicto. Lantheus Holdings (LNTH) and Novartis (NVS) are key competitors in the radiopharmaceutical therapy market.
Market Dynamics
Industry Overview
The radiopharmaceutical market is experiencing rapid growth due to advancements in targeted therapies and imaging techniques. The market is driven by the increasing prevalence of cancer and the demand for personalized medicine.
Positioning
Telix Pharmaceuticals Limited is positioned as a leader in the radiopharmaceutical market, with a focus on developing innovative diagnostic and therapeutic products for cancer. Its competitive advantage lies in its proprietary MTR technology and its strong pipeline of oncology products.
Total Addressable Market (TAM)
The total addressable market for radiopharmaceuticals in oncology is expected to reach billions of dollars in the coming years. Telix Pharmaceuticals Limited is well-positioned to capture a significant share of this market with its pipeline of innovative products.
Upturn SWOT Analysis
Strengths
- Strong pipeline of oncology products
- Proprietary MTR technology
- Experienced management team
- Regulatory approvals for key products
Weaknesses
- Reliance on clinical trial success
- High R&D expenses
- Competition from established pharmaceutical companies
- Commercialization challenges in certain markets
Opportunities
- Expansion into new cancer indications
- Strategic partnerships and collaborations
- Increasing demand for personalized medicine
- Advancements in radiopharmaceutical technology
Threats
- Regulatory hurdles and delays
- Clinical trial failures
- Patent expirations
- Competition from biosimilars and generic drugs
Competitors and Market Share
Key Competitors
- LNTH
- NVS
- GEHC
Competitive Landscape
Telix Pharmaceuticals Limited benefits from innovative proprietary technology in molecularly targeted radiation (MTR). The firm competes with larger, more established pharmaceutical companies that may have greater resources and broader market reach. Telix's competitive advantage lies in its specialized focus and pipeline innovation.
Growth Trajectory and Initiatives
Historical Growth: Telix Pharmaceuticals Limited has experienced significant growth in recent years, driven by regulatory approvals and commercialization of its key products.
Future Projections: Analyst estimates suggest continued growth for Telix Pharmaceuticals Limited, driven by the expansion of its product pipeline and increasing market demand for radiopharmaceuticals.
Recent Initiatives: Recent strategic initiatives include expansion of its manufacturing capacity, partnerships with leading research institutions, and ongoing clinical trials for its pipeline of oncology products.
Summary
Telix Pharmaceuticals is a growing biopharmaceutical company with a strong focus on radiopharmaceuticals for oncology. Its proprietary MTR technology and promising product pipeline provide significant competitive advantages. The company should focus on successfully navigating the complex regulatory landscape and managing clinical trial risks to sustain its growth trajectory. Competition from larger pharmaceutical firms and the need for continual innovation remain key challenges. Telix Pharmaceuticals has high revenue potential and can be considered to be a strong company.
Peer Comparison
Sources and Disclaimers
Data Sources:
- Company Website
- Analyst Reports
- SEC Filings
- Radiopharmaceutical Market Reports
Disclaimers:
This analysis is for informational purposes only and should not be considered financial advice. Market conditions and company performance can change rapidly, and past performance is not indicative of future results.
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
About Telix Pharmaceuticals Limited
Exchange NASDAQ | Headquaters North Melbourne, VIC, Australia | ||
IPO Launch date 2024-11-14 | Co-Founder, MD, Group CEO & Executive Director Dr. Christian P. Behrenbruch BEng(Hons), DPhil(Oxon), GAICD, J.D., M.B.A., MBA | ||
Sector Healthcare | Industry Biotechnology | Full time employees - | Website https://telixpharma.com |
Full time employees - | Website https://telixpharma.com | ||
Telix Pharmaceuticals Limited, a commercial-stage biopharmaceutical company, focuses on the development and commercialization of therapeutic and diagnostic radiopharmaceuticals. The company operates through three segments: Precision Medicine, Therapeutics, and Manufacturing Solutions. Its lead therapeutic product candidate is TLX591, a lutetium-labeled radio antibody-drug conjugate (rADC), which is in a Phase 3 clinical trial in patients with advanced prostate cancer. The company develops TLX250, an rADC for treating advanced metastatic kidney cancer; TLX101, a systemic therapy for the treatment of glioblastoma; TLX66, a product candidate for bone marrow conditioning for hematopoietic stem cell transplant conditioning; and Illuccix and Gozellix for the treatment of prostate cancer. The company is also developing TLX592, a prostate cancer therapy candidate for targeted alpha therapy based on its proprietary RADmAb-engineered antibody technology; TLX252 for the treatment of patients with advanced metastatic kidney cancer; TLX400, a bladder fibroblast activation protein for treating various tumors; TLX102, a large amino acid transporter-targeting small molecule-based alpha therapy candidate for the treatment of glioblastoma and multiple myeloma; TLX300 for treating soft tissue sarcoma; and TLX090, a bone-seeking agent for bone metastases and pain palliation. In addition, it is developing TLX250-CDx, a positron emission tomography (PET) diagnostic imaging agent for the characterization of renal masses as clear cell renal cell carcinoma; TLX101-CDx, a PET diagnostic agent to image cancerous lesions in the brain; and TLX66-CDx, a cluster of differentiation 66 imaging agent for osteomyelitis (bone infection). It operates in Australia, Belgium, Canada, the United Kingdom, the United States, and internationally. The company was founded in 2015 and is headquartered in North Melbourne, Australia.
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.